

RECEIVED

PATENT

MAR 08 2002 Attorney Docket No: 30311/35918

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Drmanac *et al.*

Serial No.: 09/479,608

Filed: January 6, 2000

For: Enhanced Sequencing by Hybridization Using Pools of Probes

Group Art Unit: 1631

Examiner: Zeman, Mary K.

RECEIVED MAR 12 1966
02 MAR - 6 PM 2:37
Sgt. TA

#17
Plunkett
3/19/02

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
Washington, D.C. 20231
Attention: Mr. Mark Spencer

Sir:

In a communication mailed January 25, 2002 (copy enclosed herewith), the Applicants were requested to provide a Substitute Sequence Listing in computer-readable form (CRF). Pursuant to telephone conversations with Robert Wax and Mark Spencer, a substitute CRF of the Sequence Listing is not necessary. The above-mentioned acknowledged that the term "Hypothetical Sequence" is acceptable as a source of material for the sequences listed in the patent application. Therefore, no substitute computer-readable copy of the Sequence Listing is needed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By: Joseph A. Williams, Jr.
Reg. No. 38659

February 5, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/479,608	01/06/2000	Radoje Drmanac	20110/35918	3272

7590 01/25/2002

Marshall, O'Toole, Gerstein, Murray & Borun
6300 Sears Tower
233 South Wacker drive
Chicago, IL 60606-6402

RECEIVED

FEB 01 2002

MARSHALL GERSTEIN

30311

EXAMINER

ZEMAN, MARY K

ART UNIT

PAPER NUMBER

1631

DATE MAILED: 01/25/2002

16

Docketed: 2/28/02

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

MAR 08 2002

TECH CENTER 1600/2900

02 MAR -6 PM 2:37
RECEIVED MAR 07 2002

**NOTICE TO COMPLY WITH
SEQUENCE RULES**

Application N .

09/479,608

Applicant(s)

DRMANAC ET AL.

Examiner

Art Unit

Mary K Zeman

1631

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reasons:

- 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked up "Raw Sequence Listing".
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. A Substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. Other:

Applicant must provide:

- An initial or A substitute computer readable form copy of the Sequence Listing.
- An initial or A Substitute paper copy of the Sequence Listing as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same, and, where applicable, include no new matter, as required by 37 CFR 1.821(e), (f), or (g) or 1.825(b) or (d).

FOR QUESTIONS PLEASE CONTACT:

Rules Interpretation (703) 308-4216
CRF Submission Help (703) 308 4212
PatentIn software help (703) 308 6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

The reply filed on 12/3/01 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): the CRF of the sequence listing was not enterable for the reasons set forth in the attached Sequence Listing Error Report. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a). Docketed: 2/28/02

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (703) 305-7133. The examiner can generally be reached between the hours of 7:00 am and 1:00 pm Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at (703) 308-4028.

Official fax numbers for this Art Unit are: (703) 308-4242, (703) 872-9306. An *unofficial* fax number, direct to the Examiner is (703) 746 5279. Please call prior to use of this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the TC1600 Receptionist whose telephone number is (703) 308-0196.

mkz
1/18/02


MARY K. ZEMAN
PRIMARY EXAMINER

